Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children
Key facts
- Where
- Daegu, Daejeon, Hwasun, Jeju City, Seongnam, Seoul, Suwon, and Yangsan, South KoreaSee the 13 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 9 years old?
Source: NCT06099366, who can take part
Where in South Korea
- Kyungpook National University Chilgok HospitalDaegu, South KoreaNot yet recruiting
- Chungnam National University HospitalDaejeon, South KoreaNot yet recruiting
- Chonnam National University Hwasun HospitalHwasun, South KoreaNot yet recruiting
- Jeju National University HospitalJeju City, South KoreaTaking people
- Seoul National University Bundang HospitalSeongnam, South KoreaTaking people
- Asan Medical CenterSeoul, South KoreaTaking people
- Korea University Anam HospitalSeoul, South KoreaTaking people
- Samsung Medical CenterSeoul, South KoreaTaking people
- Seoul National University HospitalSeoul, South KoreaTaking people
- Seoul saint Mary's HospitalSeoul, South KoreaTaking people
- Severance hospitalSeoul, South KoreaTaking people
- Ajou University Medical CenterSuwon, South KoreaTaking people
- Pusan National University Yangsan HospitalYangsan, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hee Young Ju
- Trial code
- NCT06099366
- Record updated
- 29 July 2026
- Original description
Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for high risk acute lymphoblastic leukemia in children and adolescents.Read full original descriptionShow less
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in
Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for high risk acute lymphoblastic leukemia in children and adolescents.
<Inclusion Criteria>; Newly diagnosed pediatric/adolescent acute lymphomblastic leukemia patient with NCL standard risk that stratifies all 1-4 of following; 1 year old ≤ Age < 10 years old; white blood cell at initial diagnosis < 5x10\^10/L (50,000uL); No testis involvement; Satisfaction of following organ functions; Kidney function (satisfies i or ii) i. Creatinine clearance (or radioisotope-measured GFR) ≥ 70mL/min/1.73m2 ii. Creatinine value according to age/sec satisfies the following:; 1 to < 2 years: Male: 0.6 / Female: 0.6, 2 to < 6 years: Male: 0.8 / Female: 0.8, 6 to < 10 years: Male: 1 / Female: 1, 10 to < 13 years: Male: 1.2 / Female: 1.2, 13 to < 16 years: Male: 1.5 / Female: 1.4, ≥ 16 years: Male: 1.7 / Female: 1.4 However, subjects who meet the selection criteria within 1 week before registration after receiving appropriate conservative treatment, including fluid therapy, can be registered; Liver function i. Direct bilirubin < 3.0mg/dL; <Exclusion Criteria>; Steroid administration within 2 weeks before the registration; t(9;22) or t(4;11)(q11;q23) or chromosome < 44 or iAMP21 or t(17;19)/TCF3-HLF; Newly diagnosed T cell ALL; One of the following syndromes: Down syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome, or other bone marrow failure syndrome; Burkitt leukemia/lymphoma; In the presence of electrocardiographic findings suggesting uncontrolled cardiac dysfunction (e.g., unstable ischemia, symptomatic arrhythmia, congestive heart failure) or congenital long QT syndrome; When the clinical trial subject(or legal representative) does not consent or is unable to give written consent.